As it ramps up marketing for Zoryve and preps for a new approval, Arcutis nabs new chief commercial officer from Incyte

2023-09-28
·
交易
高管变更上市批准
As it ramps up marketing for Zoryve and preps for a new approval, Arcutis nabs new chief commercial officer from Incyte
Preview
来源: FiercePharma
A new hire comes as Arcutis Biotherapeutics ramps up the commercial launch of its dermatology cream Zoryve.
With a dermatology approval in one hand and another set to come by year-end, Arcutis Biotherapeutics has hired L. Todd Edwards to help boost its commercial push.
Edwards, who has assumed the role of Arcutis' chief commercial officer, will be responsible for overseeing the ongoing commercial launch plans for two products: Zoryve, a plaque psoriasis cream that received FDA approval last summer, and a slightly modified foam version of the drug. The company is currently seeking U.S. regulatory approval of the foam version for the treatment of inflammatory skin condition seborrheic dermatitis.
Both therapies are a formulation of roflumilast, the PDE4 inhibitorPDE4 inhibitor found in AstraZeneca's oral chronic obstructive pulmonary disease treatment Daliresp.
Edwards comes with some big dermatology chops, having most recently been the group vice president and business unit head for Incyte’s immunology business, a position that saw him lead the launch and commercialization of the company's topical JAK inhibitor for atopic dermatitis.
He’s also served stints at UCB, where he helped lead the commercialization of its dermatology, rheumatology and gastroenterology portfolios, as well as at AbbVie and TAP Pharmaceuticals.
“Over many years, [Edwards] has developed a deep understanding of what is needed to be commercially successful in dermatology, and his proven track record of successfully commercializing both topical and systemic therapies will be critical in light of our ongoing launch of Zoryve cream in plaque psoriasis,” said Frank Watanabe, president and CEO of Arcutis, in a press release.
“In addition, we are excited about the impact he will have for topical roflumilast and the expected FDA approvals in other serious skin conditions including seborrheic dermatitis and atopic dermatitis.”
Ayisha Jeter, who had been serving as the pharma's interim CCO, will assume the role of senior vice president of marketing and market access. In her new position, she will lead all marketing and market access efforts at the company and report directly to Edwards.
The changes precede the FDA's official PDUFA date, which is scheduled for Dec.16 for roflumilast foam in seborrheic dermatitis. Arcutis has already initiated its marketing efforts ahead of the anticipated approval. Just this month, the company launched a new awareness and education campaign called "Clearing Up Seb Derm" aimed at increasing diagnoses of the condition.
Back in August, the pharmaceutical company also launched its first direct-to-consumer ad campaign for Zoryve, known as the "Cream That Can," which has predominately been used across streaming platforms.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。